Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03238352 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Efficacy of an Experimental Oral Rinse in Providing Long Term Relief From Dentinal Hypersensitivity
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT03238352 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 89 participants.
The verdict
NCT03238352, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
To investigate the efficacy of an experimental oral rinse, containing 1.5% potassium oxalate (KOX) and 0 parts per million (ppm) fluoride in relieving dentine hypersensitivity (DH) after 8 weeks use compared with a placebo oral rinse and a commercialized fluoride oral rinse.
Interventions
- OTHER Placebo
- DEVICE Potassium oxalate
- DRUG Sodium fluoride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2017-08-07 |
| Est. Completion | 2017-10-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03238352
The ClinicalTrials.gov registry entry for NCT03238352 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03238352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03238352 about?
NCT03238352 is a clinical study titled "A Study to Assess Efficacy of an Experimental Oral Rinse in Providing Long Term Relief From Dentinal Hypersensitivity". To investigate the efficacy of an experimental oral rinse, containing 1.5% potassium oxalate (KOX) and 0 parts per million (ppm) fluoride in relieving dentine hypersensitivity (DH) after 8 weeks use compared with a placebo oral rinse and a commercialized fluoride oral rinse.
What is the current status of trial NCT03238352?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2017-08-07. Estimated completion is 2017-10-27.
What interventions are being tested in trial NCT03238352?
The interventions under investigation include: Placebo (OTHER), Potassium oxalate (DEVICE), Sodium fluoride (DRUG).
Who is sponsoring clinical trial NCT03238352?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.